A method of breast reconstruction after breast cancer surgery using MegaFill, L&C Bio's (290650.KS) powdered acellular human dermis product, has been presented.
According to L&C Bio, Professor Han Hyun-ho of the University of Ulsan College of Medicine gave a presentation titled "Timing and Techniques of Breast Reconstruction After Neoadjuvant Therapy in Lymph Node-Positive Breast Cancer" at the Korean Breast Cancer Society 2026 Autumn Conference, held on the 17th at the Grand Josun Jeju. The presentation covered cases in which skin and soft tissue defects following breast cancer surgery were reconstructed with MegaFill.
Han explained a method combining fat grafting with MegaFill in patients who received post-mastectomy radiation therapy (PMRT), as well as an approach that injects pulverized human tissue extracellular matrix (ECM) into soft tissue defects involving the dermis to address tissue depression and asymmetry. He also outlined how to choose a grafting method by considering not only appearance but also the condition of the skin and soft tissue and the patient's treatment history.
In breast reconstruction, sheet-type acellular human dermis is surgically implanted or powdered products are injected into localized areas, depending on the extent and location of the defect. The form of the graft material is applied differently according to the degree of tissue support required and the shape of the defect.
MegaFill is a powdered human skin tissue product that L&C Bio launched in 2013. It is used to supplement tissue by grafting human dermis-derived tissue into defect areas. The company developed Rituo, a skin booster, by improving its human tissue processing technology, particle characteristics and ease of use. An L&C Bio official said both products use human dermis-derived ECM and that the company is accumulating clinical and scientific evidence tailored to each product's intended use.
The official added that the company is developing next-generation ECM products such as Rituo based on technology accumulated through human tissue graft materials including MegaDerm and MegaFill, and that it will continue to build up scientific and clinical evidence and safety data for each product.